ISRCTN24454186
Active, not recruiting
未知
Stratification in Alzheimer's disease
lster University0 sites600 target enrollmentNovember 3, 2017
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Alzheimer's disease
- Sponsor
- lster University
- Enrollment
- 600
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion criteria for age of onset Alzheimer’s disease patients:
- •1\. Male and female participants
- •2\. Aged between 45\-84
- •3\. Diagnosis of Alzheimer’s disease (50 aged 45\-54, 50 aged 55\-64, 50 aged 65\-74, 50 aged 75\-84\)
- •Inclusion criteria for ‘other dementia’ group in age of onset study:
- •1\. Male and female participants
- •2\. Aged between 45\-84
- •3\. With an ‘other’ diagnosis of dementia (i.e. NOT Alzheimer’s disease) including but not limited to: Vascular Dementia (VaD), Frontotemporal dementia (FTD), Dementia with Lewy Bodies (DLB)
- •Inclusion criteria for MCI group in age of onset study:
- •1\. Male and female participants
Exclusion Criteria
- •Exclusion criteria for all age of onset participants:
- •Participants with a bleeding disorder, for which, blood sampling would not be advisable.
- •Exclusion criteria for imaging sub study:
- •1\. Participants with a bleeding disorder, for which blood sampling would not be advisable
- •2\. Pregnancy
- •3\. Previous head or neck surgery
- •4\. Suffer from epilepsy or migraine
- •5\. Active implants (pacemaker, neurostimulator, insulin pump, ossicular prosthesis)
- •6\. May have metal fragments in the body
- •7\. Have jewellery/piercings that cannot be removed
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Establishment of dementia onset and progression model considering relevant high-risk genes after COVID-19 infection in dementia high-risk groupMental and behavioural disordersKCT0007688The Catholic University of Korea, Seoul St. Mary's Hospital65
Active, not recruiting
Phase 1
The GLP-1 receptor agonist liraglutide can slow down the progression of Alzheimer’s diseaseAlzheimer's diseaseMedDRA version: 14.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2011-000794-31-DKDept. of Pharmacology
Completed
Not Applicable
ongitudinal study across the spectrum of Alzheimer's disease associated with amyloid PET ImagingAlzheimer's diseaseJPRN-UMIN000014346Shonan-Atsugi hospital160
Active, not recruiting
Phase 1
Can a common blood pressure drug, losartan, help in Alzheimer's disease?Alzheimer's DiseaseTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2012-003641-15-GBorth Bristol NHS Trust228
Completed
Not Applicable
Alzheimer's disease, cognition and cerebrospinal fluid: Are they associated?Alzheimer's DiseaseEffect of anaesthesia and surgery on cognitionCerebrospinal fluid (CSF) predictors of cognitive change and Alzheimer's diseaeAnaesthesiology - AnaestheticsNeurological - Alzheimer's diseaseMental Health - Studies of normal psychology, cognitive function and behaviourACTRN12612000493842St. Vincent's Hospital54